🔎 Trials Near Me

Utama › Melanoma Uveal › Tennessee

Kajian klinikal Melanoma Uveal di Tennessee

6 kajian untuk Melanoma Uveal sedang mencari peserta di lokasi di Tennessee.

Bandar di Tennessee

Teks kajian rasmi (Bahasa Inggeris)

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

  • Sarah Cannon Research Institute (SCRI), Nashville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Sep 2026 · NCT07804186

A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel

  • Sarah Cannon Research Institute, Nashville
Mengambil pesertaFasa 1/2
Umur 18 hingga 70 · Semua jantina · Dikemas kini 15 Jun 2026 · NCT06940739

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

  • The Sarah Cannon Research Institute/Tennessee Oncology, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Jun 2026 · NCT03947385

Neoadjuvant Darovasertib in Primary Uveal Melanoma

  • SCRI Oncology Partners, Nashville
  • Vanderbilt Eye Institute, Nashville
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Mei 2026 · NCT07015190

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  • The West Clinic, PLLC dba West Cancer Center, Germantown
  • University of Tennessee Medical Center, Knoxville
  • Sarah Cannon Research Institute, Nashville
  • dan 1 lagi
Mengambil pesertaFasa 2/3
Semua umur · Semua jantina · Dikemas kini 2 Apr 2026 · NCT06581406

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

  • SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Nov 2025 · NCT07136181

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.